GoAI
Get started
AdaptHealth Corp. logo

AdaptHealth Corp.

AHCO

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$5.63

+$0.24 · +4.45%

Aug 21, 4:00 PM ET

AHCO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

68

Undervalued

Momentum

40

Weakening

Sentiment

69

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

AdaptHealth Corp., alongside its network of subsidiaries, delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States. The company specializes in sleep therapy, providing CPAP and bi-PAP devices and support for individuals managing obstructive sleep apnea. It also furnishes essential medical devices and provisions for diabetes treatment, such as continuous glucose monitors and insulin pumps. AdaptHealth supplies HME to patients transitioning from acute care settings, offers in-home oxygen and chronic therapy services, and caters to chronically ill patients with specialized equipment and supplies for wound care, urological, incontinence, ostomy, and nutritional needs. These services are accessible to beneficiaries of Medicare, Medicaid, and various commercial insurance payors. AdaptHealth Corp. is primarily based in Plymouth Meeting, Pennsylvania.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Suzanne Foster
Listed since
May 31, 2018
Employees
10,900

Market position

Day range

Current $5.63

52-week range

Current $5.63

Open
$5.40
Previous close
$5.39
Volume
1.92M
0.93× average
Average volume
2.07M
Average daily volume
Market cap
765.98M USD
Beta
1.46
Market reference 1
50-day average
$9.1186
-38.26% below average
200-day average
$10.1698
-44.64% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.14B USD
P/E (TTM)
-3.35×
P/B (TTM)
0.56×
P/S (TTM)
0.25×
EV / EBITDA
6.24×
Earnings yield
-5.26%
Free cash flow yield
16.30%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
10.37%
Operating margin
-0.31%
Net margin
-7.58%
Return on equity
-4.66%
Return on assets
-1.64%
Return on invested capital
5.07%

Financial health

Debt / equity
1.5×
Current ratio
1.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends26%9%-8%-25%Gross margin, FY2021: 18.15%Gross margin, FY2022: 14.05%Gross margin, FY2023: 21.30%Gross margin, FY2024: 20.89%Gross margin, FY2025: 17.52%Operating margin, FY2021: 9.19%Operating margin, FY2022: 6.41%Operating margin, FY2023: -18.70%Operating margin, FY2024: 8.09%Operating margin, FY2025: 5.74%Net margin, FY2021: 6.36%Net margin, FY2022: 2.33%Net margin, FY2023: -21.21%Net margin, FY2024: 2.77%Net margin, FY2025: -2.18%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 18.15%. Gross margin FY2022 14.05%. Gross margin FY2023 21.30%. Gross margin FY2024 20.89%. Gross margin FY2025 17.52%. Operating margin FY2021 9.19%. Operating margin FY2022 6.41%. Operating margin FY2023 -18.70%. Operating margin FY2024 8.09%. Operating margin FY2025 5.74%. Net margin FY2021 6.36%. Net margin FY2022 2.33%. Net margin FY2023 -21.21%. Net margin FY2024 2.77%. Net margin FY2025 -2.18%.

Income trends

Revenue

3.24B USD-0.49%

Operating income

186.27M USD-29.37%

Net income

−70.79M USD−161.22M USD
Income trends across reported periods3.65B USD2.08B USD503.07M USD−1.07B USDRevenue, FY2021: 2.45B USDRevenue, FY2022: 2.97B USDRevenue, FY2023: 3.2B USDRevenue, FY2024: 3.26B USDRevenue, FY2025: 3.24B USDOperating income, FY2021: 225.61M USDOperating income, FY2022: 190.41M USDOperating income, FY2023: −598.4M USDOperating income, FY2024: 263.73M USDOperating income, FY2025: 186.27M USDNet income, FY2021: 156.18M USDNet income, FY2022: 69.32M USDNet income, FY2023: −678.9M USDNet income, FY2024: 90.42M USDNet income, FY2025: −70.79M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.45B USD. Revenue FY2022 2.97B USD. Revenue FY2023 3.2B USD. Revenue FY2024 3.26B USD. Revenue FY2025 3.24B USD. Operating income FY2021 225.61M USD. Operating income FY2022 190.41M USD. Operating income FY2023 −598.4M USD. Operating income FY2024 263.73M USD. Operating income FY2025 186.27M USD. Net income FY2021 156.18M USD. Net income FY2022 69.32M USD. Net income FY2023 −678.9M USD. Net income FY2024 90.42M USD. Net income FY2025 −70.79M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.24B USD3.26B USD3.2B USD2.97B USD2.45B USD
Cost of goods sold2.68B USD2.58B USD2.52B USD2.55B USD2.01B USD
Gross profit568.56M USD681.09M USD681.77M USD417.43M USD445.61M USD
Selling, general, and administrative382.29M USD359.24M USD190.09M USD162.13M USD167.51M USD
Operating expenses382.29M USD417.36M USD1.28B USD227.02M USD220.01M USD
Interest expense105.75M USD126.67M USD130.3M USD109.41M USD95.2M USD
Depreciation and amortization413.04M USD365.33M USD420.59M USD423.44M USD258.05M USD
Operating income186.27M USD263.73M USD−598.4M USD190.41M USD225.61M USD
Net income−70.79M USD90.42M USD−678.9M USD69.32M USD156.18M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 7 misses, 1 met estimate
Average EPS surprise
-54.60%
11 comparable reports
Latest EPS result
0.06
Estimate 0.17 · Miss by 64.45%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.430.250.08-0.1Q1 '25BeatQ2 '25MetQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 0.39, estimate 0.25, surprise +56.00%, Beat. Q2 2025, reported May 6, 2025: actual 0.01, estimate 0.01, surprise 0.00%, Met estimate. Q3 2025, reported Aug 5, 2025: actual 0.01, estimate 0.15, surprise -93.33%, Miss. Q4 2025, reported Nov 4, 2025: actual 0.22, estimate 0.24, surprise -8.33%, Miss. Q1 2026, reported Feb 24, 2026: actual 0.27, estimate 0.34, surprise -20.59%, Miss. Q2 2026, reported May 5, 2026: actual -0.06, estimate 0.013, surprise -580.00%, Miss. Q3 2026, reported Aug 4, 2026: actual 0.06, estimate 0.169, surprise -64.45%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.051, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates890.91M824.51M758.11M691.71MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 856.65M USD, estimate 829.19M USD, surprise +3.31%, Beat. Q2 2025, reported May 6, 2025: actual 777.88M USD, estimate 764.77M USD, surprise +1.71%, Beat. Q3 2025, reported Aug 5, 2025: actual 800.37M USD, estimate 803.8M USD, surprise -0.43%, Miss. Q4 2025, reported Nov 4, 2025: actual 820.31M USD, estimate 799.31M USD, surprise +2.63%, Beat. Q1 2026, reported Feb 24, 2026: actual 846.29M USD, estimate 831.61M USD, surprise +1.77%, Beat. Q2 2026, reported May 5, 2026: actual 819.8M USD, estimate 796.63M USD, surprise +2.91%, Beat. Q3 2026, reported Aug 4, 2026: actual 740.31M USD, estimate 846.77M USD, surprise -12.57%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate 725.98M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.29

82.77% upside
Past 12 months12-month forecastHigh $13.00Average $10.29Low $8.00

Recent analyst actions

8 institutions
JefferiesupgradeHoldBuy
Leerink PartnersmaintainOutperform

AHCO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding AHCO

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
38.14M
Weight
0.03%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
37.39M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
27.1M
Weight
0.01%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
17.17M
Weight
0.03%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
14.24M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
13.38M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
6.23M
Weight
0.03%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares S&P Small-Cap 600 Value ETF logoiShares S&P Small-Cap 600 Value ETFIJS
Market value
5.6M
Weight
0.07%
AUM
8.33B USD
Expense ratio
0.18%
Price / 1D
$138.43+0.67%

Continue in GoAI

Research AHCO

research.disclaimer